Prometic to report its fourth quarter and year-end 2016 financial results and hold conference call webcast

March 23, 2017 Fred Dumais

LAVAL, QUEBEC, CANADA – March 23, 2017 – Prometic Life Sciences Inc. (TSX: PLI) (OTCQX: PFSCF) (“Prometic” or the “Corporation”) today announced that it will report its financial results for the fourth quarter and financial year ended December 31, 2016 on Thursday March 30, 2017 after market close.

Prometic will host a conference call at 11:00am (ET) on Friday March 31, 2017. The telephone numbers to access the conference call are 1-888-231-8191 and 647-427-7450. A live audio webcast of the conference call will be available via this link. 

An audio replay of the call will be available as of Friday March 31, 2017 at 2:00pm (ET). The numbers to access the audio replay are: 416-849-0833 and 1-855-859-2056 using the following password (91908544).

About Prometic Life Sciences Inc. Prometic Life Sciences Inc. ( is a long established biopharmaceutical company with globally recognized expertise in bioseparations, plasma-derived therapeutics and small-molecule drug development. Prometic is active in developing its own novel small-molecule therapeutic products targeting unmet medical needs in the field of fibrosis, cancer and autoimmune diseases/inflammation. A number of plasma-derived and small molecule products are under development for orphan drug indications. Prometic also offers its state of the art technologies for large-scale purification of biologics, drug development, proteomics and the elimination of pathogens to a growing base of industry leaders and uses its own affinity technology that provides for highly efficient extraction and purification of therapeutic proteins from human plasma in order to develop best-in-class therapeutics and orphan drugs. Headquartered in Laval (Canada), Prometic has R&D facilities in the UK, the U.S. and Canada, manufacturing facilities in the UK and commercial activities in the U.S., Canada, Europe, Russia, Australia and Asia.

Forward Looking Statements

This press release contains forward-looking statements about Prometic’s objectives, strategies and businesses that involve risks and uncertainties. These statements are “forward-looking” because they are based on our current expectations about the markets we operate in and on various estimates and assumptions. Actual events or results may differ materially from those anticipated in these forward-looking statements if known or unknown risks affect our business, or if our estimates or assumptions turn out to be inaccurate. Such risks and assumptions include, but are not limited to, Prometic’s ability to develop, manufacture, and successfully commercialize value-added pharmaceutical products, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of Prometic to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. You will find a more detailed assessment of the risks that could cause actual events or results to materially differ from our current expectations in Prometic’s Annual Information Form for the year ended December 31, 2016, under the heading “Risk and Uncertainties related to Prometic’s business”. As a result, we cannot guarantee that any forward-looking statement will materialize. We assume no obligation to update any forward-looking statement even if new information becomes available, as a result of future events or for any other reason, unless required by applicable securities laws and regulations. All amounts are in Canadian dollars unless indicated otherwise.

About the Author

Fred Dumais

Fred is responsible for leading Prometic’s investor relations team and is accountable for all global investor relations activity, PR and event management. He joined the company in 2001, and brings nearly twenty years of experience in investor and financial communications, as well as a deep experience of the pharmaceutical industry. He has extensive knowledge of the global financial markets in the US, Europe and his native country of Canada. Fred is a graduate from Concordia University where he gained a BA in Business Communications. He also brings to the role a background in law with a LLB from the University of Québec.

Previous Article
Prometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP
Prometic enters into binding agreement to secure $25 million follow-on financing from Structured Alpha LP

Prometic will grant Structured Alpha LP 10,600,407 warrants with an exercise price of $3.70 per common shar...

Next Article
US FDA grants orphan drug designation to Prometic’s PBI-4050 drug for the treatment of Alström Syndrome
US FDA grants orphan drug designation to Prometic’s PBI-4050 drug for the treatment of Alström Syndrome

Orphan Drug Designation is granted to drugs or biologics that treat a rare disease or condition affecting f...